AEON
AEON Biopharma, Inc.Company Information
- Company Name
- AEON Biopharma, Inc.
- CIK
- CIK0001837607
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- AEON: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AEON
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-21
- Last sale
- 2023-08-11
- Shares purchased (TTM)
- 120,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 2,841,419
- Shares outstanding
- 40,614,087
- Ownership
- 7.00%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -12.36%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 3 | 6 | 3 | 6 | 8 | 10 | 0 | 1 | 3 | 2 | 5 | 16 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Assets Current | 4 | 7 | 3 | 7 | 10 | 12 | 2 | 2 | 4 | 2 | 6 | 17 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 6 | 9 | 6 | 9 | 12 | 14 | 3 | 4 | 6 | 3 | 7 | 18 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 1 | 1 | 3 | 4 | 2 | 6 | 5 | 3 | 7 | 3 | 4 | ||||||
| Employee Related Liabilities Current | 2 | 2 | 3 | 2 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 1 | ||||||
| Sales And Excise Tax Payable Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Other Accrued Liabilities Current | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 3 | 4 | 4 | 4 | 3 | ||||||
| Liabilities Current | 7 | 7 | 7 | 8 | 9 | 9 | 14 | 11 | 10 | 16 | 13 | 14 | ||||||
| Convertible Long Term Notes Payable | 2 | 2 | 35 | 17 | 15 | 13 | 12 | 15 | 13 | 5 | - | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | 0 | ||||||
| Derivative Liabilities Noncurrent | - | - | 15 | - | - | - | - | - | - | - | - | - | ||||||
| Warrants And Rights Outstanding | 11 | 16 | 3 | 2 | 2 | 2 | 1 | 2 | 1 | 12 | 1 | 2 | ||||||
| Notes Payable Related Parties Classified Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Notes Payable Related Parties Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Other Liabilities Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 21 | 25 | 61 | 29 | 28 | 25 | 32 | 36 | 34 | 201 | 160 | 146 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 468 | 466 | 416 | 414 | 413 | 411 | 403 | 402 | 400 | 393 | 381 | 380 | ||||||
| Retained Earnings Accumulated Deficit | -484 | -483 | -471 | -434 | -429 | -423 | -432 | -434 | -428 | -592 | -474 | -447 | ||||||
| Stockholders Equity | -15 | -17 | -55 | -20 | -16 | -11 | -29 | -32 | -28 | -198 | -153 | -128 | ||||||
| Liabilities And Stockholders Equity | 6 | 9 | 6 | 9 | 12 | 14 | 3 | 4 | 6 | 3 | 7 | 18 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Related Party | 0 | 2 | 35 | 2 | 2 | 13 | 12 | 2 | 13 | - | 0 | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | ||||||
| Treasury Stock Shares | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,040 | 1,040 | 1,040 | 1,040 | 1,040 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 26 | 25 | 12 | 12 | 12 | 11 | 1 | 40 | 39 | 38 | 37 | 37 | ||||||
| Shares Outstanding | 26 | 25 | 12 | 12 | 12 | 11 | 1 | 40 | 39 | 38 | 37 | 37 | ||||||
| Treasury Stock Common Shares | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAEON Biopharma, Inc. (AEON) — SEC Financial Statements & Analysis
AEON Biopharma, Inc. (AEON) is a pharmaceutical preparations company, incorporated in DE. AEON Biopharma, Inc. trades on NYSE as: AEON. AEON Biopharma, Inc. (AEON)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, AEON Biopharma, Inc. carries a market cap of $36.33M, a P/E ratio of -0.67x, a P/B ratio of -2.37x, an enterprise value of $34.66M, and an EV/EBITDA multiple of -1.75x. On profitability, it posts a Return on Equity (ROE) of 350.00% and a Return on Assets (ROA) of -621.70%. Per share, it reports EPS of $-1.08, diluted EPS of $-1.08, free cash flow per share of $-0.27, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 3238.81% year-over-year and EPS growth of 632.82% year-over-year. On the balance sheet, it maintains a current ratio of 0.54x, a quick ratio of 0.47x, working capital of $-3.35M, a debt-to-equity ratio of -1.38x, a debt ratio of 3.6, free cash flow of $-13.65M (TTM), and net debt of $-1.68M. Figures sourced from SEC EDGAR.
- Market Cap
- $36.33M
- P/E TTM
- -0.67x
- EPS TTM
- $-1.08
- P/B TTM
- -2.37x
- ROE TTM
- 350.00%
- ROA TTM
- -621.70%
- Debt To Equity
- -1.38x
- Free Cash Flow TTM
- $-13.65M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AEON Biopharma, Inc. in?
AEON Biopharma, Inc. (AEON) operates in the Pharmaceutical Preparations industry.
What exchange does AEON trade on?
AEON Biopharma, Inc. (AEON) trades on the NYSE.
Where is AEON Biopharma, Inc. incorporated?
AEON Biopharma, Inc. is incorporated in DE.
When was AEON Biopharma, Inc. (AEON)'s most recent SEC filing?
AEON Biopharma, Inc. (AEON)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is AEON's market cap?
AEON Biopharma, Inc. (AEON) has a market capitalization of $36.33M as of 2026-06-30.
What is AEON's EPS (earnings per share)?
AEON Biopharma, Inc. (AEON)'s trailing twelve month EPS is $-1.08 as of 2026-06-30.
What is AEON's ROE (return on equity)?
AEON Biopharma, Inc. (AEON)'s trailing twelve month Return on Equity (ROE) is 350.00% as of 2026-06-30.
What is AEON's ROA (return on assets)?
AEON Biopharma, Inc. (AEON)'s trailing twelve month Return on Assets (ROA) is -621.70% as of 2026-06-30.
What is AEON's EV/EBITDA?
AEON Biopharma, Inc. (AEON)'s trailing twelve month EV/EBITDA is -1.75x as of 2026-06-30.